This article was originally published in The Gray Sheet
Device center's office of compliance and surveillance takes intitial steps toward implementation of a plan to organize OCS by areas of product jurisdiction. OCS began a "pilot program" relating to the restructuring the week of Jan. 25. The reorganization plan was floated by OCS managers in December ("The Gray Sheet" Dec. 14, p. 2).
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.